Larson Financial Group’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $147K | Buy |
3,056
+117
| +4% | +$5.97K | ﹤0.01% | 1075 |
|
|
2026
Q2 | $154K | Buy |
2,939
+748
| +34% | +$39.6K | ﹤0.01% | 961 |
|
|
2026
Q1 | $121K | Sell |
2,191
-389
| -15% | -$21.1K | ﹤0.01% | 913 |
|
|
2025
Q4 | $127K | Buy |
2,580
+523
| +25% | +$24.4K | ﹤0.01% | 851 |
|
|
2025
Q3 | $88.8K | Buy |
2,057
+464
| +29% | +$18.1K | ﹤0.01% | 949 |
|
|
2025
Q2 | $61.2K | Buy |
1,593
+953
| +149% | +$36.4K | ﹤0.01% | 1002 |
|
|
2025
Q1 | $24.8K | Sell |
640
-215
| -25% | -$7.87K | ﹤0.01% | 1284 |
|
|
2024
Q4 | $28.9K | Sell |
855
-952
| -53% | -$34.3K | ﹤0.01% | 1086 |
|
|
2024
Q3 | $73.9K | Buy |
1,807
+1,519
| +527% | +$62.1K | ﹤0.01% | 798 |
|
|
2024
Q2 | $11.1K | Sell |
288
-797
| -73% | -$33.5K | ﹤0.01% | 1230 |
|
|
2024
Q1 | $46.5K | Buy |
1,085
+200
| +23% | +$8.25K | ﹤0.01% | 708 |
|
|
2023
Q4 | $32.8K | Hold |
885
| – | – | ﹤0.01% | 733 |
|
|
2023
Q3 | $32.1K | Buy |
885
+647
| +272% | +$23K | ﹤0.01% | 716 |
|
|
2023
Q2 | $8.5K | Sell |
238
-390
| -62% | -$14K | ﹤0.01% | 981 |
|
|
2023
Q1 | $22.3K | Buy |
628
+390
| +164% | +$13.6K | ﹤0.01% | 714 |
|
|
2022
Q4 | $8.35K | Buy |
238
+1
| +0.4% | +$33 | ﹤0.01% | 915 |
|
|
2022
Q3 | $7K | Buy |
237
+1
| +0.4% | +$38 | ﹤0.01% | 875 |
|
|
2022
Q2 | $13K | Buy |
236
+2
| +0.9% | +$110 | ﹤0.01% | 637 |
|
|
2022
Q1 | $13K | Buy |
234
+4
| +2% | +$217 | ﹤0.01% | 593 |
|
|
2021
Q4 | $13K | Buy |
230
+2
| +0.9% | +$104 | ﹤0.01% | 616 |
|
|
2021
Q3 | $11K | Buy |
228
+3
| +1% | +$151 | ﹤0.01% | 577 |
|
|
2021
Q2 | $11K | Buy |
225
+3
| +1% | +$144 | ﹤0.01% | 533 |
|
|
2021
Q1 | $10K | Sell |
222
-13
| -6% | -$590 | ﹤0.01% | 542 |
|
|
2020
Q4 | $11K | Buy |
235
+5
| +2% | +$230 | ﹤0.01% | 479 |
|
|
2020
Q3 | $11K | Buy |
230
+41
| +22% | +$2.05K | ﹤0.01% | 423 |
|
|
2020
Q2 | $10K | Buy |
189
+3
| +2% | +$154 | ﹤0.01% | 396 |
|
|
2020
Q1 | $9K | Buy |
186
+2
| +1% | +$107 | 0.01% | 306 |
|
|
2019
Q4 | $11K | Buy |
184
+2
| +1% | +$111 | 0.01% | 286 |
|
|
2019
Q3 | $10K | Buy |
182
+2
| +1% | +$103 | 0.01% | 307 |
|
|
2019
Q2 | $9K | Buy |
180
+2
| +1% | +$100 | 0.01% | 257 |
|
|
2019
Q1 | $9K | Buy |
178
+3
| +2% | +$150 | 0.01% | 245 |
|
|
2018
Q4 | $8K | Buy |
+175
| New | +$8.62K | 0.01% | 240 |
|
Other funds holding GSK
Larson Financial Group's GSK Position: Q3 2026 in Review
Larson Financial Group increased its GSK (GSK) stake by 4% in Q3 2026, buying an estimated $5.97K and bringing the position to 3,056 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1075.
Larson Financial Group first reported a position in GSK in Q4 2018 and has held it in 32 quarters since. The position peaked at $154K in Q2 2026. 854 funds tracked by Wall St. Rank hold GSK as of Q3 2026.
- Larson Financial Group held 3,056 shares of GSK worth $147K as of Q3 2026.
- Larson Financial Group bought 117 GSK shares in Q3 2026, an estimated $5.97K.
- GSK made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #1075 holding.
- Larson Financial Group first reported a position in GSK in Q4 2018 and has held it in 32 quarters since.
- Larson Financial Group's GSK position peaked at $154K in Q2 2026.
- 854 funds tracked by Wall St. Rank held GSK as of Q3 2026.
Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.